Endometrial cancer is most commonly treated with surgery, and the vast majority of patients are diagnosed at an early stage where surgery alone can be curative. For decades, the standard operation was an open abdominal incision - called laparotomy - which required long hospital stays and carried significant risks, particularly because many endometrial cancer patients are overweight or obese.
Minimally invasive surgery - operating through small incisions using a laparoscope (a thin camera) - was introduced to gynecologic oncology in the early 1990s. The appeal was clear: smaller incisions mean less blood loss, fewer wound complications, shorter hospital stays, and faster recovery. In a patient population where obesity already elevates surgical risk, minimizing the trauma of surgery itself could make a meaningful difference.
By the time this review was written in 2011, three approaches to minimally invasive surgery had emerged for endometrial cancer: traditional laparoscopy, robotically assisted laparoscopy, and single-port laparoscopy. Each offered a different balance of benefits, limitations, and evidence. This article reviewed the state of the literature on all three techniques.
The most important evidence for laparoscopy in endometrial cancer came from the GOG LAP2 trial, the largest randomized comparison of laparoscopy versus laparotomy ever conducted in this disease. It enrolled 2,616 patients with clinical stage I-IIA endometrial cancer and randomly assigned them 2:1 to laparoscopy or open surgery.
The results clearly favored laparoscopy for short-term outcomes. Operative time was longer with laparoscopy (median 204 minutes vs. 104 minutes for open surgery), but hospital stay was meaningfully shorter (median 3 days vs. 4 days). Grade 2 or higher postoperative complications occurred in only 14% of laparoscopy patients versus 21% of laparotomy patients. Quality of life was significantly better in the laparoscopy group at 6 weeks, though the difference resolved by 6 months.
One important limitation was the 26% conversion rate - meaning one in four patients who started with laparoscopy needed to be switched to open surgery. The most common reason was poor visualization of the surgical field. Higher BMI, older age, and evidence of metastatic disease all increased the likelihood of conversion. Long-term survival data had not yet matured at the time of this review, though subsequent follow-up would confirm equivalent oncologic outcomes.
Robot-assisted laparoscopy became available after FDA approval in 2005 and quickly gained adoption, particularly for complex cases. The robotic system offers surgeons a 3D view, tremor-filtered movements, and articulated instrument tips that can rotate in ways that rigid laparoscopic instruments cannot. This makes intricate dissections - like lymph node removal around major blood vessels - more controllable.
In the largest series at the time (405 patients), the mean operative time was 170 minutes, mean blood loss was just 87.5 mL, and mean hospital stay was 1.8 days. Conversion to open surgery occurred in only 7%, lower than the 26% seen in the LAP2 trial for traditional laparoscopy. In a comparison study, robotic surgery patients had less blood loss (100 vs. 250 mL) and were far less likely to need a blood transfusion (3% vs. 18%) compared to traditional laparoscopy patients.
One of the most important findings was that robotic surgery appears particularly well-suited for morbidly obese patients. In a comparison of 109 obese patients (mean BMI 40) undergoing robotic surgery versus laparotomy, robotic patients had fewer transfusions, fewer complications, fewer wound problems, and shorter hospital stays. For a patient population where obesity complicates virtually every aspect of surgery and recovery, this advantage is clinically meaningful.
Robotic systems have an upfront cost of $1.5-2 million and significant annual maintenance fees. Robotic instruments can only be used for about 10 cases before they must be replaced, adding per-case cost. These expenses have led to vigorous debate about whether the benefits of robotic surgery justify its price tag.
Multiple cost analyses compared all three approaches. One found that laparotomy was the most expensive overall - primarily because of the longer hospital stay and slower return to normal activities, not because of operating room costs. Robotic surgery was only $672 more expensive than laparoscopy in one study (not statistically significant), but another found robotic surgery cost $1,469 more per case in hospital costs. A decision-analysis model estimated that traditional laparoscopy was the least expensive overall, with robotic surgery adding about $1,300 and laparotomy adding about $2,700 compared to traditional laparoscopy.
The conclusion was clear: traditional laparoscopy is the most cost-efficient minimally invasive approach. Robotic surgery costs more due to disposable instruments, but both minimally invasive approaches cost less than open surgery overall when accounting for hospitalization, complications, and recovery. The cost differential between robotic and traditional laparoscopy may be justified in settings where it enables minimally invasive surgery in patients who otherwise could not tolerate laparoscopy.
Single-port laparoscopy - also called LESS (laparoendoscopic single-site surgery) - takes minimally invasive surgery one step further by operating through a single incision, usually at the navel. Instead of three or four small incisions, all instruments enter through one port. The cosmetic result is nearly scar-free, and there are potential advantages in postoperative pain because fewer incisions heal.
The technique was first applied to gynecologic oncology in 2009, in a series of 13 patients who underwent various procedures successfully through a single incision with no postoperative complications. While promising, single-port surgery presents real technical challenges: instruments crowd each other at the single entry point, depth perception is reduced, and the technique requires considerable laparoscopic skill to begin with.
Early data suggested a learning curve of roughly 20 cases before operative times stabilized. In a feasibility study of single-port pelvic and paraaortic lymph node dissection in 21 patients with various gynecologic cancers, median operating time was 120 minutes and median lymph node counts were adequate. The authors conclude that the most exciting future direction is single-port robotic surgery, which could combine the accessibility of single-port entry with the dexterity and stability of robotic instruments, potentially overcoming the current technical limitations.
The overall conclusion of the review is that minimally invasive surgery - regardless of which platform is used - is safe, technically feasible, and almost certainly equivalent to open surgery in terms of cancer control for endometrial cancer. The main evidence gap in 2011 was long-term survival data from randomized trials, which subsequent studies would fill.
For the majority of patients, traditional laparoscopy remains the most cost-effective option and should be the first choice where the surgeon has adequate skill. Robotic surgery becomes particularly valuable when dealing with morbidly obese patients, or at institutions where robotic adoption has made the platform the standard for minimally invasive work.
The authors make an important practical point: gynecologic oncologists should maintain traditional laparoscopy skills even at institutions where robotic surgery dominates. Robotic systems may not always be available, cases may start laparoscopically before an oncologist is called, and in resource-limited settings worldwide, traditional laparoscopy may be the only minimally invasive option available. All three techniques represent genuine progress over open surgery for endometrial cancer patients.